Humana (NYSE:HUM) had its target price increased by equities researchers at Credit Suisse Group from $370.00 to $390.00 in a research note issued on Thursday, The Fly reports. The firm presently has an “outperform” rating on the insurance provider’s stock. Credit Suisse Group’s target price would suggest a potential upside of 15.06% from the stock’s previous close.
Other equities analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Piper Jaffray Companies boosted their target price on shares of Humana from $355.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, August 24th. Barclays began coverage on shares of Humana in a report on Thursday, September 13th. They issued an “overweight” rating and a $370.00 target price for the company. Argus boosted their target price on shares of Humana to $375.00 and gave the stock a “buy” rating in a report on Tuesday, September 4th. Finally, Jefferies Financial Group boosted their price target on Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $352.30.
Shares of Humana stock opened at $338.95 on Thursday. The stock has a market capitalization of $45.71 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 1.65 and a beta of 1.03. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana has a one year low of $231.90 and a one year high of $355.88.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. The business had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same period in the previous year, the company posted $3.39 earnings per share. On average, sell-side analysts anticipate that Humana will post 14.44 EPS for the current year.
In other news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the sale, the insider now owns 14,289 shares in the company, valued at approximately $4,715,370. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Stratos Wealth Partners LTD. purchased a new stake in Humana in the third quarter valued at approximately $108,000. Sun Life Financial INC boosted its position in Humana by 120.7% in the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after buying an additional 204 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in Humana by 2,984.6% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after buying an additional 388 shares during the last quarter. Smithfield Trust Co. boosted its position in Humana by 531.2% in the third quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock valued at $165,000 after buying an additional 409 shares during the last quarter. Finally, Girard Partners LTD. purchased a new stake in Humana in the third quarter valued at approximately $169,000. Hedge funds and other institutional investors own 92.62% of the company’s stock.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
See Also: Do Tariffs Work?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.